Reports
Sale
North America Tumor Ablation Market Size, Share, Analysis: By Technology: Radiofrequency (RF) Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation, Others; By Mode of Treatment: Surgical Ablation, Laparoscopic Ablation, Others; By Application; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
North America Tumor Ablation Market Outlook
The North America tumor ablation market size was valued at USD 0.71 billion in 2023, driven by the rising prevalence and incidence of cancer in the region. The market is expected to grow at a CAGR of 12.30% during the forecast period of 2024-2032, with the values likely to rise from USD 0.79 billion in 2024 to USD 2.01 billion by 2032.
Key Takeaways
- In March 2024, Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0 to treat benign bone tumors and painful bone metastases.
- The American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths caused by cancer in the United States in 2024.
- In September 2023, the United States Food and Drug Administration (FDA) approved ablation treatment planning and confirmation software, VisAble.IO, to facilitate image-guided ablation therapy.
North America Tumor Ablation Market Analysis
Tumor ablation is a minimally invasive technique in which interventional radiologists guide a needle-tipped catheter directly into a tumor, followed by applying extreme heat or cold to destroy or shrink the tumor. Imaging techniques are generally used to precisely find the tumor location. The ability of tumor ablation treatment to shrink tumors can increase the longevity of patients, relieve pain, and even in some cases, cure cancer. The technical success of the treatment and its minimally invasive nature is expected to drive the North America tumor ablation market demand in the coming years.
Cancer ranks as the second leading cause of mortality in the United States. American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths are projected to affect the United States population in 2024. The rising cancer burden directly impacts the demand for effective treatment approaches to tackle the mortality rate caused by the disease. Thus, the growing prevalence of cancer is expected to positively influence the North America tumor ablation market share in the region.
The market is witnessing a surge in approvals from health regulatory authorities such as the United States Food and Drug Administration (FDA). In March 2024, United States based Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases. The device can use four internally cooled probes at the same time and delivers 20W per channel, with the company claiming it as the most powerful bone tumor ablation on the market. Further, the company plans to introduce the product in the United States market this year. The launch of such innovative ablation systems is likely to augment the North America tumor ablation market growth in the forecast period.
The market is witnessing technological innovation in the field of tumor ablation systems which are increasing treatment precision and improving patient outcomes. In September 2023, the United States Food and Drug Administration (FDA) granted approval to ablation treatment planning and confirmation software, VisAble.IO, developed by Techsomed, an Israeli-based medical device company. The software uses the company’s artificial intelligence-driven technology called BioTrace and facilitates image-guided ablation therapy, offering various advantages such as three-dimensional visualization of the ablation target. The rising integration of artificial intelligence in tumor ablation treatment is expected to optimize patient care and fuel market growth.
Other factors that drive the market share include the rising investment from the public and private sectors, heightened public awareness regarding the benefits of the technique, and the expanding applications of tumor ablation systems.
North America Tumor Ablation Market Segmentation
North America Tumor Ablation Market Report and Forecast 2024-2032” offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Technology | Radiofrequency (RF) Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation, Others |
| Mode of Treatment | Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation, Others |
| Application | Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis, Others |
| End User | Hospitals and Clinics, Specialty Centers, Others |
| Countries | United States of America, Canada |
North America Tumor Ablation Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sonacare Medical
- Medtronic Plc
- EDAP TMS
- Angiodynamics
- Healthtronics, INC
- Johnson & Johnson
- Boston Scientific Corporation
- Misonix, INC
- Biotronik
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Mode of Treatment |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Tumor Ablation Market Overview
3.1 North America Tumor Ablation Market Historical Value (2017-2023)
3.2 North America Tumor Ablation Market Forecast Value (2024-2032)
4 North America Tumor Ablation Market Landscape*
4.1 North America Tumor Ablation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Tumor Ablation: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Mode of Treatment
5 North America Tumor Ablation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Tumor Ablation Market Segmentation (2017-2032)
6.1 North America Tumor Ablation Market (2017-2032) by Technology
6.1.1 Market Overview
6.1.2 Radiofrequency (RF) Ablation
6.1.3 Microwave Ablation
6.1.4 Cryoablation
6.1.5 Irreversible Electroporation
6.1.6 Others
6.2 North America Tumor Ablation Market (2017-2032) by Mode of Treatment
6.2.1 Market Overview
6.2.2 Surgical Ablation
6.2.3 Laparoscopic Ablation
6.2.4 Percutaneous Ablation
6.2.5 Others
6.3 North America Tumor Ablation Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Liver Cancer
6.3.3 Lung Cancer
6.3.4 Kidney Cancer
6.3.5 Bone Metastasis
6.3.6 Others
6.4 North America Tumor Ablation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospital and Clinics
6.4.3 Specialty Centers
6.4.4 Others
6.5 North America Tumor Ablation Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United States of America
6.5.3 Canada
7 United States of America Tumor Ablation Market (2017-2032)
7.1 United States of America Tumor Ablation Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Radiofrequency (RF)Ablation
7.1.3 Microwave Ablation
7.1.4 Cryoablation
7.1.5 Irreversible Electroporation
7.1.6 Others
7.2 United States of America Tumor Ablation Market (2017-2032) by Mode of Treatment
7.2.1 Market Overview
7.2.2 Surgical Ablation
7.2.3 Laparoscopic Ablation
7.2.4 Percutaneous Ablation
7.2.5 Others
7.3 United States of America Tumor Ablation Market (2017-2032) by Application
7.3.1 Market Overview
7.3.2 Liver Cancer
7.3.3 Lung Cancer
7.3.4 Kidney Cancer
7.3.5 Bone Metastasis
7.3.6 Others
7.4 United States of America Tumor Ablation Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospital and Clinics
7.4.3 Specialty Centers
7.4.4 Others
8 Canada Tumor Ablation Market (2017-2032)
8.1 Canada Tumor Ablation Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Radiofrequency (RF)Ablation
8.1.3 Microwave Ablation
8.1.4 Cryoablation
8.1.5 Irreversible Electroporation
8.1.6 Others
8.2 Canada Tumor Ablation Market (2017-2032) by Mode of Treatment
8.2.1 Market Overview
8.2.2 Surgical Ablation
8.2.3 Laparoscopic Ablation
8.2.4 Percutaneous Ablation
8.2.5 Others
8.3 Canada Tumor Ablation Market (2017-2032) by Application
8.3.1 Market Overview
8.3.2 Liver Cancer
8.3.3 Lung Cancer
8.3.4 Kidney Cancer
8.3.5 Bone Metastasis
8.3.6 Others
8.4 Canada Tumor Ablation Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospital and Clinics
8.4.3 Specialty Centers
8.4.4 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Sonacare Medical
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Medtronic Plc
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 EDAP TMS
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Angiodynamics
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Healthtronics, Inc.
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Johnson & Johnson
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Boston Scientific Corporation
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Misonix, INC
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Biotronik
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
14 North America Tumor Ablation Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 0.71 billion in 2023 driven by the rising prevalence and incidence of cancer in the region.
The market is anticipated to grow at a CAGR of 12.30% during the forecast period of 2024-2032, likely to reach a market value of USD 2.01 billion by 2032.
Technological innovations in tumor ablation systems and the rising preference for minimally invasive techniques are fuelling the demand for the market.
One of the significant trends in the market is the surge in approvals from health regulatory authorities such as the United States FDA. In March 2024 , Medtronic plc announced 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases.
Based on the technology, the market is segmented into radiofrequency (RF) ablation, microwave ablation, cryoablation, and irreversible electroporation, among others.
By mode of treatment, the market is divided into surgical ablation, laparoscopic ablation, and percutaneous ablation, among others.
End users of the market are hospitals, clinics, and specialty centers, among others.
Major application areas of tumor ablation include liver cancer, lung cancer, kidney cancer, and bone metastasis, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Sonacare Medical, Medtronic Plc, EDAP TMS, Angiodynamics, Healthtronics, INC, Johnson & Johnson, Boston Scientific Corporation, Misonix, INC, and Biotronik.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER